Structural Heart Disease: TAVR for low-risk patients after 2 years | A look at the future? | 3-year TMVR outcomes

News You Need to Know Today

Thursday, March 4, 2021

Editor's Choice: Structural Heart Disease

TAVR outperforms surgery for low-risk patients after 2 years—but the gap may be shrinking

After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.

The American College of Cardiology and American Heart Association have collaborated on a new update to the much-discussed 2021 chest pain guidelines. The American College of Emergency Physicians and Society for Cardiac Angiography and Interventions also contributed to the document.

TAVR outperforms surgery for low-risk patients after 2 years—but the gap may be shrinking

After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.

A look at the future? Engineers propose a new design for mechanical heart valves

The team behind the new-look valves hope their design will limit blood clots and boost patient care.

A look at the future? Engineers propose a new design for mechanical heart valves

The team behind the new-look valves hope their design will limit blood clots and boost patient care.

TMVR associated with improved outcomes for heart failure patients after 3 years

This latest analysis is an extension of the COAPT trial, which had examined the safety and effectiveness of TMVR with the MitraClip device after two years.

Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

TMVR associated with improved outcomes for heart failure patients after 3 years

This latest analysis is an extension of the COAPT trial, which had examined the safety and effectiveness of TMVR with the MitraClip device after two years.

Cardiologist donates $1M to fund heart disease research as tribute to ‘selfless, loving’ wife

The funds will go toward establishing the Carol S. O’Neill Structural Heart Disease Research Fund.

Cardiologist donates $1M to fund heart disease research as tribute to ‘selfless, loving’ wife

The funds will go toward establishing the Carol S. O’Neill Structural Heart Disease Research Fund.

‘I have so much hope now’: Patient thrives after undergoing 2 heart valve replacement procedures

Both procedures were a part of a clinical trial—and both occurred at the same facility.

‘I have so much hope now’: Patient thrives after undergoing 2 heart valve replacement procedures

Both procedures were a part of a clinical trial—and both occurred at the same facility.

Can COVID-19 lead to bioprosthetic valve thrombosis? What specialists need to know

“To our knowledge, this is the first report of prosthetic aortic valve thrombosis associated with COVID-19 infection,” the authors wrote.

Hackensack Meridian Health, New Jersey’s largest health network, recently announced it has signed a definitive agreement with Complete Care to acquire a majority of its long-term care facilities.

Can COVID-19 lead to bioprosthetic valve thrombosis? What specialists need to know

“To our knowledge, this is the first report of prosthetic aortic valve thrombosis associated with COVID-19 infection,” the authors wrote.

Direct oral anticoagulants safer than warfarin for AFib patients with bioprosthetic heart valves

The analysis, published in the American Journal of Cardiology, focused on both the safety and effectiveness of these two treatment options.

Direct oral anticoagulants safer than warfarin for AFib patients with bioprosthetic heart valves

The analysis, published in the American Journal of Cardiology, focused on both the safety and effectiveness of these two treatment options.

Researchers examine ‘concerning’ out-of-hospital 30-day mortality rate for TAVR patients

Researchers examined data from more than 98,000 patients who underwent transfemoral TAVR from January 2015 to March 2018.

Researchers examine ‘concerning’ out-of-hospital 30-day mortality rate for TAVR patients

Researchers examined data from more than 98,000 patients who underwent transfemoral TAVR from January 2015 to March 2018.

Explained: 4 key takeaways from the 2020 ACC/AHA valvular heart disease guidelines

Two specialists have shared their own perspective on the updated ACC/AHA guidelines in Circulation.

Explained: 4 key takeaways from the 2020 ACC/AHA valvular heart disease guidelines

Two specialists have shared their own perspective on the updated ACC/AHA guidelines in Circulation.

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us | Unsubscribe from all | Privacy Policy

© Innovate Healthcare, a TriMed Media brand

Editor's Choice: Structural Heart Disease

Recent Newsletters